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Abstract
Glioblastoma is one of the most aggressive, lethal and in curable primary brain tumors with a dismal prognosis in humans. Mango
ginger ( Curcuma amada ) and hops (Humulus lupulus ) are two botanicals containing phytochemicals with potential anticancer
effects. We have investigated the anticancer and antimetastatic properties of supercritical CO2 extract of mango ginger (CA)
and ethanol extract of hops (HL) in the U-87MG human glioblastoma cell line. Both CA and HL individually demonstrate strong
cytotoxicity against glioblastom a cells. CompuSyn analysis of cytotoxicity data confirms that CA and HL are synergistic for
cytotoxicity with combination index (CI) values of <1.0. Additionally, CA and HL individually as well as the combination significantly
inhibit MMP-2 and MMP-9 activity, tumor cell migration (transendothelial cell migration assay) and AKT phosphorylation in U-87
MG cells. CA and HL inhibit glycolysis in U-87MG cells as indicated by the inhibition of ATP and lactate synthesis with the CA+HL
combination demonstrating strong inhibition of glycolysis via the reduction of ATP and lactate synthesis compared to cells treated
by each extract alone. CA and HL treatment down regulates the expression of proteins associated with metastasis, MMP-2 and
MMP-9 and up regulates the expression of TIMP1. Proteins associated with apoptosis, inflammation and energy metabolism
were also modulated by CA and HL treatment of glioblastoma cells. These results suggest that CA and HL can be combined for
the therapeutic management of glioblastomas.
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Introduction
Glioblastoma is the most common primary malignant brain tu-
mor in adults with an incidence rate of 3.19 per 100,000 per-
sons in United States. It is one of the most aggressive, lethal
and incurable human tumors with a survival time of 12-15
months in patients undergoing standard of care treatment in-
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volving surgery, chemotherapy and radiation therapy. Generally,
chemotherapy options for high-grade gliomas are very much
limited due to the poor penetration of the blood-brain barrier
and/or drug resistance of tumor cells [1].
Hops ( Humulus lupulus L) is a dioecious, perennial plant be-
longing to the Cannabaceae family, which is a raw material of
beer that serves as an important source of phenolic compounds
imparting stability, bitter taste and flavor to the beer. The use of
hops as a medicinal plant has more than 2000 years of history [2]
. The ancient healers used hops against leprosy, foot odor, con-
stipation, and for blood purification [3] . Hops have been consid-
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ered to be an important source of substances having estrogenic
effects and therefore, they are common components of commer-
cial dietary supplements for women with menopausal symptoms
or hormonal imbalances [4, 5] . The polyphenols, essential oils,
bitter acids ( a and β-bitter acids) and the various compounds in
each of these constituents in hops are reported to possess anti-
oxidant, anti-inflammatory, antimicrobial, anticancer and antian-
giogenic properties [3, 5–9] .
The dried hops contain 14% polyphenols, mainly phenolic
acids, prenylated chalcones, flavonoids, catechins and proantho-
cyanidins [10–12]. In addition, hops provide a resin consisting
of bitter compounds such as humulones and lupulones [10, 13]
. Prenylflavonoids, a subclass of flavonoids with restricted dis-
tribution in the plant kingdom but present in hops, display
diverse molecular activities including distinct anti-proliferative
activity towards human cancer cells and suppression of can-
cer cell invasion [8, 14] . Two interesting prenylflavonoids
with antiproliferative activity are 6-prenylnaringenin (6-PN)
and 8-prenylnaringenin (8-PN). Their common precursor com-
pound xanthohumol (XN), a prenylated chalcon, is the principal
prenylflavonoid in the female flowers of hop plant and provides
80-90% of its total flavonoid content [15] . During the beer
brewery process XN can isomerize into isoxanthohumol (IX),
which can subsequently be converted to 8-PN by gut bacteria.
Additionally, XN precursor desmethoxyxanthohumol sponta-
neously isomerizes into 6-PN and 8-PN after addition of the hop
cones into the boiling wort in the brew kettle [16] .
In our earlier investigations, we have reported extensively on
the anticancer properties of CA, a proprietary supercritical CO2
extract of mango ginger ( Curcuma amada Roxb.) both in vitro
and in vivo in human glioblastoma cell lines [ 17-20]. CA can be
combined with conventional cancer drugs like vinbalstine, cy-
clophosphamide, temozolomide, etoposide and irinotecan with
synergistic cytotoxic effects [17–19] . The main objective of cur-
rent study was to investigate anticancer properties of an ethano-
lic extract of hop s (HL) and synergetic effects with CA in human
glioblastoma cells including evaluation of molecular signaling
pathways related to inhibition of proliferation and invasion of
glioblastoma cells.
Materials and methods
Cell line and Cell Culture
Human glioblastoma cell line (U-87MG) was purchased from
American Type Culture Collection, Manassas, VA and the cells
were grown in RPMI medium supplemented with 10% FBS and
antibiotics in a humidified 5% CO2 incubator.
Extracts
Supercritical CO2 extract of mango ginger ( CA) and an extract
of hops (HL) prepared with 90% ethanol were obtained from
Flavex Naturextrakte GmbH, Rehlingen, Germany. The usual
yield of CA extract was 2.5-3% of dried rhizome. The prod-
uct is brownish and contains 10.2% of steam volatile compo-
nents. Quantitative analysis by HPLC and GC-MS showed the
presence of 61.7% (E)-labda-8(17),12diene-15,16 dial (LDD),
5.6% beta myrcene, 0.8% beta pinene, 0.3% ocimene, 0.2% beta
cariophyllene besides other essential oil components in trace
amounts. The chemical fingerprint details of CA have been de-
scribed in our earlier publication [20]. HL is a dark green, al-
most black pasty extract with typical hop smell. It is standard-
ized to 33% humulones by addition of about 20% organic olive
oil. HPLC analysis showed that it contains 32.3% humulones
(alpha acids), 15.9% lupulones (beta acids) and 1.5% xanthohu-
mol.
Cytotoxicity assay
Glioblastoma cells were treated with increasing concentrations
of CA, HL or their combination in RPMI medium for 72
h in 96 well plates. MTT [3-(4,5-Dimethyl thiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay performed with the Cell
Proliferation Kit I (Roche Biochemicals, IN) was used to an-
alyze cytotoxicity of CA. The experiments were repeated four
times with three replications for each treatment and the IC50,
IC75 as well as IC90 values were calculated from absorbance
readings [17, 18] .
CompuSyn Analysis
To determine the synergistic/additive/antagonistic effects be-
tween CA and HL, cytotoxicity data was analyzed further using
CompuSyn software (CompuSyn Inc., Paramus, NJ). This pro-
gram is based on Chou and Talalay’s multiple drug effect equa-
tions and defines synergism as a more-than expected additive ef-
fect and antagonism as a less-than expected additive effect [21]
. The combination index was calculated by the Chou-Talalay ’s
equations for multiple drug effects, which take into account po-
tency (inhibitory concentration values) and shape (slope, m) of
dose-effect curve [21, 22].
Analysis of MMP activity by zymography
The gelatinases MMP-2 and MMP-9 are two members of the
MMP family that have been studied extensively owing to their
consistent association with tumor invasion and metastasis. To
assess the MMP activity, tumor cells were treated with increas-
ing concentrations of CA and/or HL for 72h and total protein
was extracted using Invitrogen protein extraction buffer and 100
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m g protein was separated on 10% SDS-PAGE containing 1%
gelatin [17, 18] . The gel was incubated in renaturing solution
for 30 min, followed by two incubations of developing solution
30 min each time, and then stained with coomassie blue stain for
1 h. The gels were destained overnight with destaining solution
until areas of gelatinase activity appeared as clear sharp bands
over the blue background [23]. The bands were quantified using
Unscan software and plotted against CA and/or HL concentra-
tions.
Tumor cell transendothelial migration assay
The calorimetric QCM tumor cell transendothelial cell migra-
tion assay kit (Millipore) was used to analyze the ability of tu-
mor cells to invade the endothelium. To perform this assay, hu-
man vascular endothelial cells (HUVEC) cells (105 /250 ml/well
of F15 medium supplemented with FBS and antibiotics) were
plated in each Boydon chambers and allowed to grow for 72 h
in the CO2 incubator until the endothelial cells formed a mono-
layer. The endothelial cells were activated with 20 ng/ml recom-
binant human TNF-α for 18 h by incubating in a CO2 incubator
at 37◦C. On the fifth day, U-87MG tumor cells were harvested
and resuspended in serum-free RPMI medium containing only
0.5% FBS. The medium was removed from HUVEC cells grow-
ing in Boydon chambers and tumor cells (105 /well in 0.25 ml of
serum free medium) were added into the Boydon chambers. The
insert chambers were then transferred to wells containing 300 ml
of serum free RPMI medium. Once the cells were settled (after 1
h) both insert chambers and wells containing serum free medium
were treated with increasing concentrations of CA and/or HL (0-
20 µg/ml). The multiwell plate containing HUVEC+U-87MG
cells was incubated in a CO2 incubator at 37◦C for 24 h. The
invasion of tumor cells across the endothelium is determined by
measuring the number of cells that migrate to the lower cham-
ber. The inner plate is stained with cell staining solution for 15
min. The excess stain was washed with distilled water and stain
was extracted from migrated tumor cells using 200 µl of stain
extraction solution. The absorbance of the extracted stain was
measured at 450 nm in a plate reader and the inhibition (%) of
tumor cell migration by CA and/or HL was estimated as com-
pared to the untreated control sample [19] .
Analysis of AKT Phosphorylation
U-87MG glioblastoma cells (2x106 /5ml) was treated with in-
creasing concentrations of CA and/or HL (0- 50 µg/ml) for 72 h
and total cellular proteins were isolated using lysis buffer from
the Cell Signaling Technology, Inc., Danvers, MA. The concen-
trations of protein in the lysate were estimated by the Lowrie’s
method. The phosphorylated form of AKT in the cellular lysate
equivalent to 10 µg protein was analyzed using the Surveyor IC
human phospho-AKT Pan Specific ELISA kit according to man-
ufacturer’s instructions ( Cell Signaling Technology, Inc., Dan-
vers, MA). The relative phospho-AKT levels of U-87MG cells
under increasing concentrations of CA were plotted [19] .
ATP Assay
U-87MG human glioblastoma cells (104 /100 µl medium/well)
were plated in 96-well plates and incubated overnight at 37◦C
in a CO2 incubator. On the next day, cells were treated with in-
creasing concentrations of CA and/or HL for 5 h in the CO2
incubator. The plates were kept for 10 min at room tempera-
ture and 100 µl of Cell Titer–Glo reagent (Promega Corporation,
Madison, WI) was added into the wells and mixed thoroughly
for 10 times. The plates were shaken on an orbital shaker for 10
min and kept at room temperature for another 10 min for stabi-
lization of luminescent signal and 100 µl of sample was trans-
ferred to a fresh 96-well plate before the plates were read in the
Veritas Luminometer. The ATP in each well was calculated con-
sidering the ATP level in the control (untreated) as 100%. The
experiment was repeated four times and the average values plot-
ted [24].
Lactate Assay
U-87MG human glioblastoma cells ( 2 x105 /ml/well) were
plated in 24-well plates and treated with increasing concentra-
tions of CA and/o r HL followed by incubation at 37◦C in a
CO2 incubator. About 0.5ml medium was collected from each
well for estimation of lactate and 1 ml of 8% perchloric acid was
added into the media. The mixture was mixed well on a vortex
and kept at 4◦C for 5 min. and centrifuged for 10 min at 1500 xg.
About 25 µl of the extract was combined with the 1.475 m l of
working solution containing nictotinamide adenine dincleotide
hydrate (NAD), glycine buffer and lactate dehydrogenase for 30
min at room temperature. The plates were read at 340 nm within
10 min. The relative amounts of lactate in the medium was cal-
culated based on the lactate standard curve and plotted against
drug concentrations [24].
Western Blot Analysis
U-87MG cells (5 x106 /5 ml) were treated with increasing con-
centration of CA (0-100 µg/ml) and/or HL for 72 h and total
cellular protein was extracted using 0.5 ml of Invitrogen pro-
tein extraction buffer (Invitrogen Corporation, Frederick, CA).
The protein concentration was determined and 100 µg protein
was separated on 7.5% SDS-PAGE. The separated protein was
blotted on a nitrocellulose filter. The filters were hybridized with
anti-human monoclonal/polyclonal antibodies specific for each
protein (Bax, Bcl-2, BNIP3, p21, p53, caspase 3, MMP2, TIMP1
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and β-tubulin control) in a western blot procedure and detected
using the alkaline phosphatase color detection kit (Bio Rad Lab-
oratories, Hercules, CA). The relative expression of proteins
compared to untreated control samples were quantified using
UNSCAN-IT gelTM software (Silk Scientific, Inc., Orem, UT).
The relative increase or decrease in protein level was calculated
based on untreated sample and fold-level changes were plotted
against CA concentration [17–19].
Statistical Analysis
Mean and standard deviation estimates were calculated using
Microsoft Excel software using data from three separate experi-
ments. The dose-dependent trends in relative mRNA and protein
expression were ascertained with samples treated with increas-
ing CA concentrations. The relative protein expression levels
(fold change) at different CA concentrations were statistically
analyzed by 1-way analysis of variance, and the treatments were
compared with control treatment using Dunnett’s comparison
test (GraphPad Prism software, La Jolla, CA). The protein ex-
pression data was statistically compared with the expression of
house keeping control gene (β-actin) using unpaired t test with
Welch’s correction and the significance level presented in the
graph (*p <0.05, **p <0.01 and *** p <0.001).
Results
Cytotoxicity of CA, HL and CA+HL
The results of cytotoxic studies are presented in Fig. 1 and Ta-
ble 1. Both CA and HL are strongly cytotoxic to glioblastoma
cells with HL more cytotoxic than CA at the IC50 value (3.72
vs. 5.03 mg/ml respectively) and CA more cytotoxic at IC75 and
IC90 values (12.87 and 37.14 vs. 22.93 and 43.87 mg/ml respec-
tively). When the two extracts were combined there was signifi-
cant reduction in IC values indicating synergism. The cytotoxic
values for CA+HL combination are 2.70, 7.35 and 11.64 mg/ml
at IC50, IC75 and IC90 levels, respectively.
The compuSyn analysis of cytotoxicity was performed to de-
termine the synergism/additive effect/antagonism between CA
and HL. The dose-effect curve and median-effect plots presented
in Fig. 2A and B show the potentiating effect of combination.
The combination plot (Fig. 2C) and polygonogram (Fig. 2D)
show the synergism between CA and HL in glioblastoma. Syner-
gism is also illustrated by the combination index values given in
Table 2. The CI values are all below 1 indicating the synergistic
cytotoxic effect between CA and HL.
Matrix metalloproteinase activity
Zymograms indicating the effect of CA, HL and CA +HL are
shown Fig. 3A and quantified activity data are presented in Fig.
Figure 1 Cytotoxicity of CA, HL andCA+HL extracts in U87-MG
human glioblastoma cell line. Tumor cells were treated withextracts
for 72 h and cytotoxicity analyzed using Cell Proliferation kit I(MTT).
3B. CA has a dose-dependent inhibition of MMP2 and MMP9
activity in glioblastoma cells. HL has a pronounced effect on
MMP activities and shut down the MMP2 and MMP9 activity
right from the lowest concentration of 2 m g/ml onwards. The
combination has similar inhibitory effect on MMP2 and MMP9
as HL alone.
Table 1 Cytotoxicity ofsupercritical CO2 extract of mango ginger (CA),
hops (HL) and their combinationin U-87MG human glioblastoma cell line
Treatment IC50 (mg/ml) IC75 (mg/ml) IC90 (mg/ml)
CA 5.02 ± 0.10 12.87 ± 0.25 37.14 ± 0.19
HL 3.72 ± 0.03 22.93 ± 0.42 43.87 ± 1.04
CA + HL 2.70 ± 0.05 7.35 ± 0.21 11.64 ± 0.31
Table 2 Combination Index (CI) values between CA and HL in U-87MG
cellline
Combination CI at IC50 CI at IC75 CI at IC90
CA+HL 0.744 0.540 0.406
<0.1 very strong synergism, 0.1-0.3 strongsynergism,
0.3-0.7 synergism, 0.8-0.9 moderateto slight synergism,
0.9-1.1 nearlyadditive, 1.1-1.45 moderate to slight antag-
onism, 1.45-3.3 antagonism
Cell migration
The results of cell migration analyzed by transendothelial mi-
gration assay are presented in Fig. 4. CA inhibits cell migration
of tumor cells in a dose-dependent manner with approximately
62.5% and 48.5% migration at 10 m g/ml and 20 m g/ml con-
centrations, respectively, compared to untreated cells. The HL
inhibition rate is greater than for CA, with about 47.6% and
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Figure 2 CompuSyn analysis ofcytotoxicity data for determining synergy/additive effect/antagonism betweenethanolic extract of hops (HL) and
supercritical CO2-extract ofmango ginger (CA) in U-87MG human glioblastoma cell line. (A) Dose-effect plotof CA, HL and CA+HL); (B) Median
effect plot for CA, HL and CA+HL); (C)Combination index (CI) plot showing all CI values less than 1 indicatingsynergism between CA and HL.
Figure 3 Inhibition of MMP-2 and MMP-9 activity in U-87MGcells by
CA, HL and CA+HL extracts. (A) Zymography gels showing MMP-2
and MMP-9bands decreasing with increasing concentrations of
extracts (B) Graphs showingthe quantification of MMP bands plotted
against extract concentrations.
32.2% migration at 10 m g/ml and 20 m g/ml concentrations.
The CA+HL combination is superior to either agent alone in in-
hibiting tumor cell migration, with about 33.2% and 30.9% cell
migration at 5 m g/ml and 10 m g/ml concentrations. At the high-
est dose (20 m g/ml), the CA+HL combination has comparable
level of inhibition of cell migration as HL alone.
Inhibition of AKT activity
Both CA and HL significantly inhibit AKT activity significantly,
although HL is more effective than CA, particularly at lower
Figure 4 Inhibition of tumor cell migration in U-87MG cells by CA,
HL and CA+HL extracts analyzed by tumor cell transendothelial
migration assay.
concentrations. (Fig. 5 ). CA inhibits AKT activity by about 70%
and 80% at 20 and 50 m g/ml concentrations. HL inhibits 85% of
AKT activity at 5 m g/ml and 91% at 50 m g/ml concentrations.
The CA+HL combination inhibits 90% and 93% AKT activity
at 20 m g/ml and 50 m g/ml concentrations, respectively.
I nhibition of cellular ATP
CA and HL inhibit ATP synthesis in U-87MG cells with CA
demonstrating greater inhibition than HL (Fig. 6). While CA in-
hibits 88.3% ATP at 20 m g/ml concentration, HL inhibits only
51.5% ATP at that concentration. CA inhibits ATP almost com-
pletely at 50 m g/ml concentration while HL inhibits 94 % at
50 m g/ml dose. The CA+HL combination demonstrates greater
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Figure 5 Inhibition of AKT phosphorylation by CA, HL andCA+HL
treatment in U-87MG cell line. Phosphorylated form of AKT was
analyzedusing Pathscn ELISA kit from Cell Signaling Technology
inhibition of ATP synthesis in glioblastoma cells than either ex-
tract alone. The combination treatment inhibited 95% ATP at 20
m g/ml and complete inhibition at 50 m g/ml.
Figure 6 Inhibition of ATP synthesis by CA, HL and CA+HL
treatment in U-87MG cell line. Note the increased inhibition of ATP
synthesis by the combination compared to the single agents.
Inhibition of cellular lactate
Many tumor cells utilize the glycolysis pathway under aerobic
conditions generating high amount of lactate in order to meet
the increased demand for ATP for cell proliferation unlike nor-
mal cells. Therefore, we have analyzed whether CA and/or HL
inhibits lactate production which is an indirect indicator of gly-
colytic activity. Both CA and HL individually and in combina-
tion inhibit lactate synthesis in glioblastoma cells (Fig. 7 ). The
inhibition appeared to be dose-dependent, with 50 µg /ml CA
showing the highest inhibitory effect (60%) on lactate produc-
tion. HL reduces the cellular lactate concentration only 40 % at
50 m g/ml. The CA+HL combination demonstrates a greater ef-
fect than individual agents alone, with the lactate concentration
at 38% at 20 m g/ml.
Figure 7 Inhibition of lactate synthesis by CA, HL and CA+HL
treatment in U-87MG cell line. Note the increase in lactate inhibition
by high concentrations of CA+HL
Expression of proteins associated with metastasis,
apoptosis, inflammation and energy metabolism
The results of western blot hybridization analysis of the pro-
tein expression of genes associated with metastasis, apoptosis,
inflammation and energy metabolism are presented in Fig. 8
and 10. The quantification of protein expression is presented in
Fig. 9 and 11. Among the three metastasis-associated genes an-
alyzed, CA and HL treatment appears to down regulate MMP-2
and MMP-9, the latter biomarker being down regulated more
than the former. Also the tumor inhibitor of metallo proteinase
protein 1 (TIMP1) is up regulated by higher doses of CA and
HL as well as all the combination treatments. All the genes as-
sociated with apoptosis (mutant p53, BNIP3, BAX, Bcl-2 and
caspase-3 were modulated by CA, HL and CA+HL treatments.
p53, BNIP3, and Bcl-2 were down regulated while BAX and
caspase-3 were up regulate d significantly. The house-keeping
gene GAPDH showed no statistical difference between treat-
ments. A dose-dependent regulation of genes associated with
apoptosis (mutant p53, BNIP3, Bcl-2) and inflammation (COX-
2, eNOS, HIF-1 a and mTOR) were quite apparent with CA+HL
combination treatments.
Discussion
The traditional use of mango ginger and hops has suggested po-
tential anticancer and other medicinal properties. The supercrit-
ical CO2 extract prepared from the rhizomes of mango ginger
(CA) contains 61.7% dialdehyde LDD that is shown to have cy-
totoxic effects against a variety of human cancer cell lines in
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Figure 8 (A) Effect of CA, HL and CA+HL treatment on the
expression of protein biomarkers associated with metastasis and
apoptosis inU-87MG cell line analyzed by western blot hybridization.
vitro and in vivo [18, 20, 25, 26] . Previously, we have shown that
CA affect a n array of cellular biochemical pathways in cancer
cells inducing the tumor cell death [16–19] . CA also demon-
strates synergistic cytotoxic effects with conventional cancer
drugs like vinblastine, etoposide, temozolomide and irinotecan
in rhabdomyosarcoma and glioblastoma cell lines [18, 19] .
The use of hops as a medicinal plant in addition to its ma-
jor use in brewing industry is well known [2, 3] . The ethanolic
extract of hop contains alpha-acids, beta-acids and xanthohumol
which are reported to have anti-inflammatory, anticancer and es-
trogenic properties [15, 27–29] . The prenylflavonoids and bitter
acids from hops have been shown to possess antiproliferative
and anti-inflammatory effects [5, 14, 29] . In the present study,
we have shown that CA and HL have synergistic effect on cy-
totoxicity in glioblastoma cells, as indicated by the CI values
of < 1. Additionally, HL has significant antimetastatic effects
because of its inhibitory effect on MMP activity. Both MMP-
2 and MMP- 9 were inhibited with lower doses of HL treat-
ment in glioblastoma cells. Furthermore, there is inhibition of
tumor cell migration in the transendothelial assay by HL treat-
ment with the CA+HL combination being more efficacious than
treatment with individual agents alone. HL also inhibits AKT ac-
tivity significantly in glioblastoma cells. These attributes of CA
and HL indicate that these agents have potential for treatment of
glioblastoma. We have previously reported on the inhibition of
MMP-2 and MMP-9 expression by CA in glioblastoma cells in
vitro [20] . Desai et al. [30] reported that META060, a modified
hops extract inhibits TNF-alpha- or LPS-mediated MMP-9 lev-
els and enzyme activity. Furthermore, xanthohumol, a flavonoid
from hop s inhibits MMP activity [31] . Similarly, myricetin
and quercetin, two flavonoids present in hops extract have been
shown to inh ibit MMP-2 and MMP-9 expression, indicating the
anti-angiogenic properties of these compounds [32–34] .
The role of AKT on the survival and growth of cancer cells
is well-established. Many human cancers including glioblas-
tomas exhibit frequent activation of Akt that correlate s with
advanced disease and /or poor prognosis [35] . The penetra-
tion of circulating tumor cells into the endothelium is a crucial
step in tumor metastasis. We have previously shown that CA
treatment significantly inhibits cell migration in glioblastoma
cells in a dose-dependent manner [18] . Cell migration is one
of the pre-requisites of metastasis and glioblsatomas are one of
the highly metastatic malignancies in humans. Cancer invasion
and metastasis involve the degradation of extracellular matrix in-
volving matrix metalloproteinases (MMPs), especially MMP-2
and MMP-9 [36–38] . In the present investigation, the CA+HL
combination treatment inhibited the tumor cell migration more
than the individual agents. Also HL and CA+HL have inhib-
ited the both expression and activities of MMP-2 and MMP-9
and up regulated the expression of TIMP1 protein expression.
Further, HL (in addition to CA) and the CA+HL combination
down regulate the phosphorylation of AKT. Many tumor cells
utilize aerobic glycolysis with reduced oxidative phosphoryla-
tion for glucose metabolism, a phenomenon referred to as the
Warburg effect and glioblastomas has been shown to have a pref-
erential metabolism of glucose through aerobic glycolysis. Re-
cently we showed that the combination of CA with glycolytic in-
hibitors such as 2-Deoxy-D-glucose (2-DG) and S odium oxam-
ate (SO) inhibit growth, proliferation and migration of glioblas-
toma cells [24] . CA+HL combination in the present study has
more inhibitory effect on lactate and ATP synthesis indicating
the superior effect on inhibition of glycolytic pathway than CA
or HL alone. Such increased inhibition of glycolysis for drug
combinations compared to single agents has been reported in
breast cancer cells [39, 40] and glioblastoma cells [24] .
Gene expression studies in the current study indicated that
CA , HL and the CA+HL combination up regulate the expres-
sion of pro-apoptotic genes (BAX and caspase 3) and down
regulate anti-apoptotic genes (mutant p53, BNIP3 and Bcl-2).
Furthermore, the combination down regulates markers associ-
ated with inflammation and energy metabolism such as COX-2,
iNOS, AMPK a, HIF-1 a and mTOR proteins. In a recent study,
we reported that CA could down regulate these markers and the
fact that the CA+HL combination is synergistic suggests that
evaluation of this combination for therapeutic management of
glioblastoma is warranted. In conclusion, the results from this
investigation indicate the anticancer and antimetastatic proper-
ties of CA and HL and the feasibility of combining these two
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Figure 9 Quantification of expression of protein markers(western blots) associated with metastasis and apoptosis in U-87MG cell line. The relative
expression levels (fold level) are plotted against extract concentrations. The significant difference between treatments was estimated by1-way
analysis of variance with Dunnett’s multiple comparison test (GraphPadPrism software, La Jolla, CA) (*p< 0.05, **p <0.01, ***p < 0.001).
Figure 10 Effect of CA, HL and CA+HL on the expression of protein
markers associated with inflammation and energy metabolism in
U-87MG cell line analyzed by western blot hybridization.
biological extracts against glioblastoma, the validity of which
has to be analyzed in animal models and human trials.
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